Recent news on Exemestane

Breast Cancer Prevention Trial in Limbo  -  May 8, 2007
Journal of American Medical Association (subscription),Two other large trials of aromatase inhibitors—in these cases, exemestane and anastrozole—are already under way. Because these are placebo-controlled

Switching from Tamoxifen to Aromatase Inhibitor Improves Survival ...  -  Apr 11, 2007
Cancer Consultants (press release),Currently available aromatase inhibitors include Arimidex® (anastrozole), Aromasin® (exemestane), and Femara® (letrozole). When considering how best to use

Breast cancer patients' treatment response may help reveal cancer ...  -  Apr 6, 2007
News from Washington University in St. Louis,Three drugs — exemestane (Aromasin®), letrozole (Femara®) and anastrozole (Arimidex®) — fight breast cancer by lowering the amount of estrogen the body

Over 10000 UK Breast Cancer Patients Could Become Eligible Within ...  -  Apr 4, 2007
PharmaLive.com (press release),Lower mortality rates were shown in patients who had switched to the aromotase inhibitor, Aromasin (exemestane), after 2-3 years of the current standard

New Breast Cancer Survival Data From The Intergroup Exemestane ...  -  Feb 13, 2007
Medical News Today (press release),New data from the Intergroup Exemestane Study (IES), published in the Lancet today show that, 2 to 3 years after the end of their treatment,

New breast cancer drug Exemestane shows great potential to save lives  -  Feb 13, 2007
News-Medical.net,The researchers found that switching from the breast cancer treatment Tamoxifen to the new drug Exemestane after two or three years resulted in death rates

Switching treatment to exemestane after 2-3 years on tamoxifen ...  -  Feb 13, 2007
News-Medical.net,The Intergroup Exemestane Study (IES), an extensive, international study, tested the superiority of switching to exemestane (an aromatase inhibitor) from

Breast Cancer Survival Rates Improved By Novel Drug Sequence, Say ...  -  Feb 16, 2007
Medical News Today (press release),The new paper shows that switching to a drug called exemestane, two to three years after commencing standard therapy with the drug tamoxifen,

Breast cancer drug 'could save many lives'  -  Feb 13, 2007
Ireland Online,Switching from the gold-standard breast cancer treatment tamoxifen to the new drug exemestane after two or three years resulted in death rates falling by

Study Published In British Medical Journal The Lancet Shows ...  -  Feb 14, 2007
Medical News Today (press release),Research from the Intergroup Exemestane Study (IES) published today in The Lancet shows for the first time that patients who switched to Aromasin after

Switching Breast Cancer Drugs Reduces Relapse  -  Feb 13, 2007
Medical News Today,An international trial has shown that switching from tamoxifen to exemestane afer 2 to 3 years increases disease-free survival and shows a slightly reduced

Cancer Drug Switch Could Boost Survival Rates  -  Feb 12, 2007
Life Style Extra,But a new paper has shown that switching to a drug called exemestane half way through can cut the chances of dying in these women by a further 17 per cent,

New Treatment Improves Breast Cancer Survival  -  Feb 13, 2007
Keep the Doctor Away,The new paper published in the Lancet shows that switching to a drug called exemestane, two to three years after commencing standard therapy with the drug

Study Published in British Medical Journal The Lancet Shows ...  -  Feb 13, 2007
PharmaLive.com (press release),HOUSTON, Feb.13, 2007 /PRNewswire/ -- Research from the Intergroup Exemestane Study (IES) published today in The Lancet shows for the first time that

Further Evidence Supporting a Switch to Aromasin® Following Two to ...  -  Feb 16, 2007
Cancer Consultants (press release),Researchers affiliated with the Intergroup Exemestane Study have reported that postmenopausal women with hormone-positive breast cancer achieve improved

Further Evidence Supporting a Switch to Aromasin® Following Two to ...  -  Feb 14, 2007
Cancer Consultants (press release),Researchers affiliated with the Intergroup Exemestane Study recently conducted a clinical trial to further evaluate switching to an aromatase agent after

Breast cancer drug could further reduce mortality  -  Feb 14, 2007
Cancer Research UK - News & Resources,A study published online in the Lancet suggests breast cancer patients who switch drugs from tamoxifen to exemestane (Aromasin) are more likely to survive

Breast cancer drug promises hope  -  Feb 12, 2007
Guardian Unlimited,Switching from the gold-standard breast cancer treatment tamoxifen to the new drug exemestane after two or three years results in death rates falling by 17%

Switching From Tamoxifen To An Aromatase Inhibitor Could Improve ...  -  Feb 14, 2007
Medical News Today (press release),Switching treatment to exemestane after 2-3 years on tamoxifen, improves disease-free survival* and seems to modestly reduce risk of death, according to an

New Drug Therapy for Breast Cancer Offers Hope  -  Feb 13, 2007
MedIndia,According to scientists, switching over from the standard breast cancer therapy drug tamoxifen, to another one exemestane, could cut related deaths by

UK research claims new breast cancer relapse drug  -  Feb 13, 2007
People's Daily Online,The new drug exemestane for breast cancer treatment could improve survival rates by 17 percent, new research shows. A study of 4742 post-menopausal women

Ulster cancer victims given wonder drug  -  Feb 13, 2007
Belfast Telegraph,Research has shown that Exemestane or Aromasin is so effective in fighting the disease that it can reduce the risk of dying from breast cancer by 17%

Switching From Tamoxifen to an Aromatase Inhibitor Could Improve ...  -  Feb 13, 2007
DG NewsLONDON, UK -- February 13, 2007 -- Switching treatment to exemestane after 2–3 years on tamoxifen, improves disease-free survival* and seems to modestly

New cancer drugs may save 1300 lives a year, tests show  -  Feb 12, 2007
Guardian Unlimited,Switching to exemestane, the drug used in the trial, can cut the risk of death by 17%, compared with staying on tamoxifen alone for all five years.

Switching drugs could cut breast cancer deaths  -  Feb 13, 2007
Manchester.com,Switching patients from tamoxifen to exemestane could significantly reduce the number of women dying from post-menopausal breast cancer, research has shown.

New cancer drug to save a thousand lives a year  -  Feb 12, 2007
Times Online,A study of 4742 post-menopausal women found that switching from the present gold-standard breast cancer treatment tamoxifen to the new drug exemestane after

Switching Breast Cancer Drugs May Boost Survival  -  Feb 14, 2007
WFIE-TV,The Intergroup Exemestane Study (IES) tracked more than 10000 breast cancer patients for a median follow-up of almost five years. The researchers looked at

Aromasin® Compromises Bone Health in Breast Cancer Patients  -  Jan 26, 2007
Cancer Consultants (press release),According to an article recently published in the Lancet, women with breast cancer who switch from tamoxifen (Nolvadex®) to Aromasin® (exemestane) have an

Aromasin® Compromises Bone Health in Breast Cancer Patients  -  Jan 31, 2007
Cancer Consultants (press release),Skeletal effects of exemestane on bone mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer

Newer breast cancer drugs save lives, study finds  -  Feb 13, 2007
CNNAromatase inhibitors include anastrozole, made by AstraZeneca Plc under the brand name Arimidex, and exemestane, made by Pfizer Inc. under the brand name

Newer breast cancer drugs save lives, study finds  -  Feb 11, 2007
Scotsman,Aromatase inhibitors include anastrozole, made by AstraZeneca under the brand name Arimidex, and exemestane, made by Pfizer Inc. under the brand name

Funding can depend on where you live  -  Feb 5, 2007
ic Wales,Exemestane – a hormonal therapy also known as Aromasin – 34 issues were made at a cost of £3100 in 2006. Nice guidance was issued for this in November 2006

Hormone Drug Type Makes Survival Difference In Advanced Breast Cancer  -  Feb 2, 2007
Medical News Today (press release),Several aromatase inhibitors, including anastrozole (Arimidex), exemestane (Aromasin) and letrozole (Femara) have been available for clinical use for the

New Faslodex(TM) (fulvestrant) Data Fill 'treatment Gap' For Women ...  -  18 Jan 2007
Medical News Today (press release),AstraZeneca has announced the first results from a major clinical trial, EFECT (Evaluation of Faslodex vs Exemestane Clinical Trial), at the annual San

Analysis: Stopping breast-cancer return  -  Dec 19, 2006
Science Daily (press release)In these women, who had experienced disease progression after first-line treatment following cancer recurrence, the use of either fulvestrant or exemestane

Aromasin® and Faslodex® Similarly Effective and Safe As Second ...  -  Jan 2, 2007
Cancer Consultants (press release),According to results recently presented at the 2006 San Antonio Breast Cancer Symposium (SABCS), Aromasin (exemestane) and Faslodex (fulvestrant)

Adjuvant Exemestane After Tamoxifen Improves Relapse- and Disease ...  -  Dec 18, 2006
DG NewsSAN ANTONIO, TX -- December 18, 2006 -- Postmenopausal women with hormone receptor-positive breast cancer who received exemestane after 5 years of tamoxifen

Exemestane After Tamoxifen Improves Breast Cancer Survival  -  Dec 18, 2006
Cancerpage.com,The finding reveal that exemestane following tamoxifen reduces breast cancer recurrence "by about half," reported Dr. Terry Mamounas of the Aultman Health

Fulvestrant Equivalent to Exemestane in Second-Line Treatment ...  -  Dec 18, 2006
DG NewsThe study -- Evaluation of Faslodex vs Exemestane Clinical Trial (EFECT) -- represents the first phase 3 clinical trial of this treatment in this patient

Analysis: Stopping breast-cancer return  -  Dec 19, 2006
Science Daily (press release)In these women, who had experienced disease progression after first-line treatment following cancer recurrence, the use of either fulvestrant or exemestane

New Faslodex(TM) (Fulvestrant) Data Fill 'Treatment Gap' for Women ...  -  Dec 16, 2006
campus med,8.3 months for exemestane (retrospective analysis, no statistical analysis performed). "The EFECT data are extremely valuable to clinicians, as they provide

New Faslodex(TM) (Fulvestrant) Data Fill 'Treatment Gap' for Women ...  -  Dec 16, 2006
Nieuwsbank (abonnement),At the time of analysis, 288 patients (82.1) receiving the 'Faslodex' regimen had progressed compared with 299 (87.4) receiving exemestane with a median TTP

Aromasin after tamoxifen ups breast cancer survival  -  Dec 19, 2006
Scientific AmericanThe finding shows that Aromasin, known technically as exemestane, following tamoxifen reduces breast cancer recurrence "by about half," reported Dr. Terry

New Faslodex(TM) (Fulvestrant) Data Fill 'Treatment Gap' for Women ...  -  Dec 16, 2006
Juraforum.de,AstraZeneca (NYSE:AZN) today announced the first results from a major clinical trial, EFECT (Evaluation of Faslodex vs Exemestane Clinical Trial),

SABCS: Aromasin Ranks High for Efficacy in Unfinished Trial  -  Dec 18, 2006
MedPage Today,18 -- If a big study of the post-tamoxifen use of Aromasin (exemestane) for early breast caner had gone to its conclusion, the aromatase inhibitor would

New Study Demonstrates Efficacy Of Pfizer's Aromasin For Early ...  -  Dec 19, 2006
Medical News Today (press release),According to Professor Charles Coombes, lead investigator for the landmark Intergroup Exemestane Study (IES) and director of cancer medicine,

New Data On Pfizer's Aromasin and Ellence to Be Presented at San ...  -  Dec 14, 2006
PR Newswire (press release),Key data presentations include: PRODUCT TIME ABSTRACT TITLE AROMASIN(R) Benefit from exemestane as extended (exemestane Dec. 15 adjuvant therapy after five

Aromasin® and Faslodex® Similarly Effective and Safe in Previously ...  -  Dec 18, 2006
Cancer Consultants (press release),According to results recently presented at the 2006 annual San Antonio Breast Cancer Symposium, Aromasin® (exemestane) and Faslodex® (fulvestrant)

SABCS: Aromasin and Faslodex Found Equivalent in Advanced Breast ...  -  Dec 16, 2006
MedPage Today,Advise patients who ask that this study suggests that Aromasin (exemestane) and Faslodex (fulvestrant) are equivalent when used to treat women with advanced

New Data On Pfizer's Aromasin and Ellence to Be Presented at San ...  -  Dec 14, 2006
Drug Newswire (press release),14 /PRNewswire-FirstCall/ -- Results of two studies evaluating the hormonal therapy Aromasin(R) (exemestane tablets) and the chemotherapy Ellence(R)

Certain types of cancer becoming more common  -  Dec 15, 2006
SpiritIndia,Aromasin (exemestane tablets) after five years of tamoxifen were 56% less likely to have a relapse of breast cancer than those who received placebo.

New Data On Pfizer's Aromasin and Ellence to Be Presented at San ...  -  Dec 14, 2006
Earthtimes.org14 -- Results of two studies evaluating the hormonal therapy Aromasin(R) (exemestane tablets) and the chemotherapy Ellence(R) (epirubicin hydrochloride

Excellent prospects  Oct 24, 2006
The Excel Study, which launched last year, is examining the aromatase inhibitor Aromasin (exemestane) to see if it prevents the disease from developing in ... -Ottawa Sun, Clinical trials at Geisinger  Oct 17, 2006
A study of hormone therapy, using exemestane, to see how well it works compared to anastrozole in preventing cancer recurrence in postmenopausal women who have ... -Wilkes Barre Times-Leader, Aromatase Inhibitors Prolong Survival Over Tamoxifen  Sep 21, 2006
They referred specifically to four third-generation aromatase inhibitors -- Femara (letrozole), Aromasin (exemestane), Arimidex (anastrazole), and the ... -MedPage Today

Aromatase Inhibitors Improve Survival in Women with Advanced ...  Sep 22, 2006
More recently introduced aromatase inhibitors or inactivators, such as Arimidex® (anastrozole), Aromasin® (exemestane), and Femara® (letrozole), reduced ... -Cancer Consultants

Wonder Drugs  Sep 15, 2006
Duarte, Calif. Currently, three AIs have FDA approval: Arimidex (anastrazole), Aromasin (exemestane) and Femara (letrozole). Studies ... -Golf For Women Magazine

NICE Recommends Exemestane (AROMASIN TM) As An Option, Within Its ...  -  Nov 25, 2006
Medical News Today (press release),Exemestane is the only treatment option recommended by NICE as an alternative to continued tamoxifen for women who have already received two to three years

Breast cancer hope for thousands  -  Nov 21, 2006
Guardian Unlimited,Research has shown that switching to the aromatase inhibitor exemestane after two or three years of tamoxifen treatment can cut the risk of breast cancer

NICE Publishes Final Guidance For Aromatase Inhibitors, UK  -  Nov 22, 2006
Medical News Today (press release),Exemestane (Aromasin), Pfizer: Indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer,

Drug watchdog backs new breast cancer drugs  -  Nov 22, 2006
Scotsman,Anastrozole made by AstraZeneca under the brand name Arimidex, letrozole sold by Novartis as Femara and exemestane marketed as Aromasin by Pfizer are

Switching from Tamoxifen to Arimidex® Linked with Improved Survival  -  Nov 21, 2006
Cancer Consultants (press release),Currently available aromatase inhibitors include Arimidex® (anastrozole), Aromasin® (exemestane), and Femara® (letrozole). When considering how best to use

Women wanted for clinical breast cancer trial  Jun 30, 2006
...disease. Exemestane blocks the formation of estrogen, a hormone that has been known to increase the chance of developing breast cancer. ... -NorthernLife.ca

Switching to Aromasin After Tamoxifen May Reduce Risk of ...  Jun 22, 2006
The researchers wanted to know if switching to Aromasin (chemical name: exemestane), an aromatase inhibitor, after 2 to 3 years of tamoxifen would reduce the ... -Breastcancer.org

Raloxifene Again Found to Deter Breast Cancer in Older Women, plus ...  Jul 17, 2006
June 3, 2006 - New data from the Intergroup Exemestane Study (IES) showed for the first time today that hormone sensitive postmenopausal early breast cancer ... -SeniorJournal.com

Aromasin Receives FDA Approval for Adjuvant Treatment of Early ...  Jun 30, 2006
The US Food and Drug Administration (FDA) has approved Aromasin® (exemestane tablets) for adjuvant treatment of postmenopausal women with estrogen-receptor ... -Cancer Consultants

Volunteers still needed to test new drug  Jun 21, 2006
...for post-menopausal women with increased risk of breast cancer to participate in a clinical trial to evaluate the role of a new drug called ExCel (exemestane). ... -NorthernLife.ca

After Tamoxifen: promising results from new breast cancer drugs  Jul 13, 2006
...chemotherapy and/or hormonal treatment. One recent study involved Aromasin (exemestane), marketed by Pfizer. It confirmed that switching ... -Times Online

CGRMC News  Jul 12, 2006
...patients. The three are anastrozole, exemestane and letrozole, and they work by blocking the conversion of androgens into estrogen. ... -Casa Grande Valley Newspapers



Evista Prevents Invasive Breast Cancer in High Risk Post ...  Apr 17, 2006
The 800-pound gorilla in the room was another drug class-the aromatase inhibitors, notably Femara (letrozole), Arimidex (anastrozole), and Aromasin (exemestane ... - MedPage Today

Lilly's Evista rivals tamoxifen in breast cancer  Apr 18, 2006
At present these agents - which include AstraZeneca's own Arimidex (anastrozole), Novartis' Femara (letrozole) and Pfizer's Aromasin (exemestane) - are not yet ... - Pharma Times (subscription)





Exemestane May Help Downgrade Tumours Scheduled for Mastectomy to ...  Mar 27, 2006
NICE, FRANCE -- March 27, 2006 -- The aromatase inhibitor exemestane (Aromasin) could make breast-conserving surgery possible in breast cancer patients with ... - DG News

A 62-Year-Old Woman With a New Diagnosis of Breast Cancer  Mar 21, 2006
...receptors. Adjuvant endocrine therapy was recommended. Exemestane was considered; however, it was not covered by her insurance. She ... - Journal of American Medical Association (subscription)

Neoadjuvant Aromatase Inhibitors May Be as Effective as ...  Mar 27, 2006
...were randomised to pre-operative treatment with either an aromatase inhibitor -- consisting of either anastrazole (Arimidex) or exemestane (Aromasin) -- or ... - DG News

New findings in breast cancer therapy described  Mar 30, 2006
The third-generation aromatase inhibitors (AIs) anastrozole, exemestane, and letrozole offer new treatment options, although their efficacy has not been ... - Therapeutics Daily (subscription)

Pay attention to your breasts  Mar 11, 2006
...cancer cells. There are three aromatase inhibitors available in the market now ie anatrazole, letrozole and exemestane . Recently ... - Malaysia Star

Optimising Herceptin-based Therapy in HER2-positive Metastatic ...  Feb 22, 2006
...there are a number of trials that will be looking at trastuzumab in combination with hormonal therapy, such as with tamoxifen, exemestane, anastrozole (TAnDEM ... - DG News

Buddies For Life: Medication May Prevent Some Forms Of Breast ...  Feb 8, 2006
...“The drug that we're testing is a drug called aromasin or the generic is exemestane,� said Doctor Joanne Mortimer with the Moores UCSD Cancer Center. ... - KFMB,

Buddies For Life: Medication May Prevent Some Forms Of Breast ...  Feb 8, 2006
...“The drug that we're testing is a drug called aromasin or the generic is exemestane,� said Doctor Joanne Mortimer with the Moores UCSD Cancer Center. ... - KFMB

Warning of risk of from vaginal oestrogen  Jan 26, 2006
...risks in prescribing vaginal oestrogen to breast cancer patients being treated with the new aromatase inhibiting drugs, anastrozole, letrozole and exemestane[1 ... - News-Medical.net

Vaginal Dryness Meds May Counteract Breast Cancer Drugs  Jan 26, 2006
Aromatase inhibitors (AIs) such as anastrozole, letrozole and exemestane are increasingly being used for breast cancer treatment in postmenopausal women. ... - Forbes

Women With Breast Cancer Beware  Jan 25, 2006
According to research using such aromatase inhibitors as anastrozole (Arimidex), letrozole (Femara) and exemestane (Aromasin) may stop new cancer drugs from ... - Ivanhoe

The drug that may improve the outcome for high-risk women  Jan 20, 2006
These three drugs for the hormonal treatment of breast cancer are Arimidex (anastrozole), Femara (letrozole) and Aromasin (exemestane). ... - Times Online

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional